All In Biotech

Drug Trial Radar · NCT05841381

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive and Lymph Node Negative Invasive Breast Cancer

Last checked: Nov 19, 2026Latest source record: May 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 876 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

876

Planned (sponsor's estimate)

Start

May 6, 2023

Primary completion

May 6, 2028

Study completion May 6, 2033

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, phase III study evaluating the efficacy and safety of Pyrotinib in Combination With Trastuzumab and paclitaxel in patients HER2 Positive and lymph node negative invasive Breast Cancer

Conditions

  • Breast Cancer

Interventions

  • PyrotinibDrug

    pyrotinib: 400mg orally daily for 1 year

  • TrastuzumabDrug

    8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles

  • PaclitaxelDrug

    80mg/m2 per week for a total of 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease free survivalTime frame: 5 year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.